Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 57

1.

Systematic discovery of multicomponent therapeutics.

Borisy AA, Elliott PJ, Hurst NW, Lee MS, Lehar J, Price ER, Serbedzija G, Zimmermann GR, Foley MA, Stockwell BR, Keith CT.

Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7977-82. Epub 2003 Jun 10.

2.

Effects of cytokines and fluconazole on the activity of human monocytes against Candida albicans.

Baltch AL, Smith RP, Franke MA, Ritz WJ, Michelsen PB, Bopp LH.

Antimicrob Agents Chemother. 2001 Jan;45(1):96-104.

3.

A high-throughput screening assay for small molecules that disrupt yeast cell integrity.

Krysan DJ, Didone L.

J Biomol Screen. 2008 Aug;13(7):657-64. doi: 10.1177/1087057108320713. Epub 2008 Jul 14.

PMID:
18626115
4.

Candida and candidaemia. Susceptibility and epidemiology.

Arendrup MC.

Dan Med J. 2013 Nov;60(11):B4698. Review.

PMID:
24192246
5.

In vitro and in vivo activity of a novel antifungal small molecule against Candida infections.

Wong SS, Kao RY, Yuen KY, Wang Y, Yang D, Samaranayake LP, Seneviratne CJ.

PLoS One. 2014 Jan 22;9(1):e85836. doi: 10.1371/journal.pone.0085836. eCollection 2014.

6.

Novel high-throughput screen against Candida albicans identifies antifungal potentiators and agents effective against biofilms.

LaFleur MD, Lucumi E, Napper AD, Diamond SL, Lewis K.

J Antimicrob Chemother. 2011 Apr;66(4):820-6. doi: 10.1093/jac/dkq530. Epub 2011 Jan 28.

7.

Combination of fluconazole with non-antifungal agents: a promising approach to cope with resistant Candida albicans infections and insight into new antifungal agent discovery.

Liu S, Hou Y, Chen X, Gao Y, Li H, Sun S.

Int J Antimicrob Agents. 2014 May;43(5):395-402. doi: 10.1016/j.ijantimicag.2013.12.009. Epub 2014 Jan 22. Review.

PMID:
24503221
8.

Synthesis and antifungal activity of 1,2,3-triazole containing fluconazole analogues.

Aher NG, Pore VS, Mishra NN, Kumar A, Shukla PK, Sharma A, Bhat MK.

Bioorg Med Chem Lett. 2009 Feb 1;19(3):759-63. doi: 10.1016/j.bmcl.2008.12.026. Epub 2008 Dec 10.

PMID:
19110424
9.

A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients.

Parihar R, Nadella P, Lewis A, Jensen R, De Hoff C, Dierksheide JE, VanBuskirk AM, Magro CM, Young DC, Shapiro CL, Carson WE 3rd.

Clin Cancer Res. 2004 Aug 1;10(15):5027-37.

10.

In vitro interactions between farnesol and fluconazole, amphotericin B or micafungin against Candida albicans biofilms.

Katragkou A, McCarthy M, Alexander EL, Antachopoulos C, Meletiadis J, Jabra-Rizk MA, Petraitis V, Roilides E, Walsh TJ.

J Antimicrob Chemother. 2015 Feb;70(2):470-8. doi: 10.1093/jac/dku374. Epub 2014 Oct 6.

11.

Application of a human tumor colony-forming assay to new drug screening.

Shoemaker RH, Wolpert-DeFilippes MK, Kern DH, Lieber MM, Makuch RW, Melnick NR, Miller WT, Salmon SE, Simon RM, Venditti JM, et al.

Cancer Res. 1985 May;45(5):2145-53.

12.

Synergistic effect of calcineurin inhibitors and fluconazole against Candida albicans biofilms.

Uppuluri P, Nett J, Heitman J, Andes D.

Antimicrob Agents Chemother. 2008 Mar;52(3):1127-32. doi: 10.1128/AAC.01397-07. Epub 2008 Jan 7.

13.

Design and synthesis of new fluconazole analogues.

Pore VS, Agalave SG, Singh P, Shukla PK, Kumar V, Siddiqi MI.

Org Biomol Chem. 2015 Jun 21;13(23):6551-61. doi: 10.1039/c5ob00590f. Epub 2015 May 15.

PMID:
25975803
14.

Antifungal effect of Echinophora platyloba on expression of CDR1 and CDR2 genes in fluconazole-resistant Candida albicans.

Khajeh E, Hosseini Shokouh SJ, Rajabibazl M, Roudbary M, Rafiei S, Aslani P, Farahnejad Z.

Br J Biomed Sci. 2016;73(1):44-8. doi: 10.1080/09674845.2016.1155269.

PMID:
27182677
15.

Novel hybrids of fluconazole and furanones: design, synthesis and antifungal activity.

Borate HB, Sawargave SP, Chavan SP, Chandavarkar MA, Iyer R, Tawte A, Rao D, Deore JV, Kudale AS, Mahajan PS, Kangire GS.

Bioorg Med Chem Lett. 2011 Aug 15;21(16):4873-8. doi: 10.1016/j.bmcl.2011.06.022. Epub 2011 Jul 13.

PMID:
21757344
16.

High-throughput synergy screening identifies microbial metabolites as combination agents for the treatment of fungal infections.

Zhang L, Yan K, Zhang Y, Huang R, Bian J, Zheng C, Sun H, Chen Z, Sun N, An R, Min F, Zhao W, Zhuo Y, You J, Song Y, Yu Z, Liu Z, Yang K, Gao H, Dai H, Zhang X, Wang J, Fu C, Pei G, Liu J, Zhang S, Goodfellow M, Jiang Y, Kuai J, Zhou G, Chen X.

Proc Natl Acad Sci U S A. 2007 Mar 13;104(11):4606-11. Epub 2007 Mar 5.

18.

Mechanism-based pharmacokinetic-pharmacodynamic models of in vitro fungistatic and fungicidal effects against Candida albicans.

Venisse N, Grégoire N, Marliat M, Couet W.

Antimicrob Agents Chemother. 2008 Mar;52(3):937-43. doi: 10.1128/AAC.01030-07. Epub 2008 Jan 7.

19.

Antifungal activity of azole compounds CPA18 and CPA109 against azole-susceptible and -resistant strains of Candida albicans.

Calabrese EC, Castellano S, Santoriello M, Sgherri C, Quartacci MF, Calucci L, Warrilow AG, Lamb DC, Kelly SL, Milite C, Granata I, Sbardella G, Stefancich G, Maresca B, Porta A.

J Antimicrob Chemother. 2013 May;68(5):1111-9. doi: 10.1093/jac/dks506. Epub 2013 Jan 4.

PMID:
23292344
20.

A repurposing approach identifies off-patent drugs with fungicidal cryptococcal activity, a common structural chemotype, and pharmacological properties relevant to the treatment of cryptococcosis.

Butts A, DiDone L, Koselny K, Baxter BK, Chabrier-Rosello Y, Wellington M, Krysan DJ.

Eukaryot Cell. 2013 Feb;12(2):278-87. doi: 10.1128/EC.00314-12. Epub 2012 Dec 14.

Supplemental Content

Support Center